Fierce Pharma June 20, 2024
On a revised dealmaking spree this year, Korea’s Samsung Biologics is re-tooling its long-running drug manufacturing pact with Baxter Healthcare.
The retooled deal, first established back in July of 2017, will now see Baxter pay Samsung upwards of $223 million for its manufacturing services through end of 2034. Previously, Baxter was on the hook to pay just $15 million for Samsung’s production assistance.
The update to the accord reveals Baxter as the subject of Samsung’s 2017 production tie-up. At the time the deal was announced, the company was keeping the identity of its client under wraps, Korea Biomedical Review reports.
It isn’t immediately clear what types of drugs or products Samsung will help produce for Baxter under the contract manufacturing...
Today's Sponsors
Today's Sponsor